Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-30
2007-10-30
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S465000
Reexamination Certificate
active
11059771
ABSTRACT:
The present application describes modulators of MCP-1 of formula (I):or stereoisomers or pharmaceutically acceptable salts thereof, wherein X, Z, a, b, c, d, bond g, n, s, R1, R2, R4, R5, R10, R12, and R13, are as defined above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.
REFERENCES:
patent: 5869496 (1999-02-01), Hale et al.
patent: 6011052 (2000-01-01), Padia et al.
patent: 6013644 (2000-01-01), Mills et al.
patent: 6784200 (2004-08-01), Duncia et al.
patent: 6821964 (2004-11-01), Colon-Cruz et al.
patent: 2005/0192276 (2005-09-01), Batt et al.
patent: 2005/0197325 (2005-09-01), Batt et al.
patent: 2005/0197373 (2005-09-01), Batt et al.
patent: WO94/29309 (1994-12-01), None
patent: WO97/44329 (1997-11-01), None
patent: WO98/06703 (1998-02-01), None
patent: WO99/07351 (1999-02-01), None
patent: WO99/07678 (1999-02-01), None
patent: WO99/25686 (1999-05-01), None
patent: WO99/40913 (1999-08-01), None
patent: WO99/40914 (1999-08-01), None
patent: WO 00/46196 (2000-08-01), None
patent: WO 00/69815 (2000-11-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 02/50019 (2002-06-01), None
patent: WO02/060859 (2002-08-01), None
patent: WO02/070523 (2002-09-01), None
patent: WO 02/081449 (2002-10-01), None
patent: WO03/091245 (2003-11-01), None
patent: WO03/092568 (2003-11-01), None
patent: WO03/093231 (2003-11-01), None
patent: WO03/099773 (2003-12-01), None
patent: WO03/101970 (2003-12-01), None
patent: WO03/105853 (2003-12-01), None
patent: WO 2003101970 (2003-12-01), None
patent: WO2004/007472 (2004-01-01), None
patent: WO2004/009550 (2004-01-01), None
patent: WO2004/009588 (2004-01-01), None
patent: WO 2004/010942 (2004-02-01), None
patent: WO2004/010943 (2004-02-01), None
patent: WO 2004/011418 (2004-02-01), None
patent: WO 2004/011427 (2004-02-01), None
patent: WO 2004/011443 (2004-02-01), None
patent: WO2004/012671 (2004-02-01), None
U.S. Appl. No. 11/060,250, filed Feb. 17, 2005, Batt et al.
Forbes, Ian T. et al.,“CCR2B Receptor Antagonists:Coversion of a Weak HTS Hit to a Potent Lead Compound”, Bioorg. Med. Chem. Lett. vol. 10, pp. 1803-1806 (2000).
Mirzadegan, Tara et al., “Indentification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists”, The Journal of Biological Chemistry vol. 275 No. 33, pp. 25562-25571 (2000).
Baba, et al “A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity”, Proc. Natl. Acad. Sci, vol. 96, pp. 5698-5703 (1999).
Batt Douglas G.
Carter Percy H.
Anderson Rebecca
Bogie Terence J.
Bristol--Myers Squibb Company
Chung Susannah
LandOfFree
Substituted bicycloalkylamine derivatives as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted bicycloalkylamine derivatives as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted bicycloalkylamine derivatives as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3839336